Novartis AG NVS
Novartis AG (NYSE: NVS) is a cardio-renal-metabolic drug developer. Its lead program, Entresto (sacubitril/valsartan), is in Phase 3 for Heart failure (HFrEF, HFpEF, pediatric). Its next catalyst on record is delpacibart braxlosiran (del-brax): Planned FDA meeting on next steps in FSHD (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: delpacibart braxlosiran (del-brax) — Planned FDA meeting on next steps in FSHD (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Entresto | Heart failure | small molecule | Approved |
| Cosentyx | Not stated in extract | antibody | Approved |
| Kisqali | Not stated in extract | small molecule | Approved |
| Xolair | Not stated in extract | antibody | Approved |
| Mayzent | Not stated in extract | small molecule | Approved |
| Rydapt | Not stated in extract | small molecule | Approved |
| delpacibart zotadirsen (del-zota) | Duchenne muscular dystrophy, exon 44 skipping (DMD44) | RNA (siRNA/ASO/mRNA) | Phase 3 |
| delpacibart etedesiran (del-desiran) | Myotonic dystrophy type 1 | RNA (siRNA/ASO/mRNA) | Phase 3 |
| abelacimab | Stroke and systemic embolism prevention in atrial fibrillation | antibody | Phase 3 |
| pacibekitug | Atherosclerotic cardiovascular disease | antibody | Phase 3 |
| delpacibart braxlosiran (del-brax) | Facioscapulohumeral muscular dystrophy (FSHD) | RNA (siRNA/ASO/mRNA) | Phase 2 |
| farabursen | Autosomal dominant polycystic kidney disease | oligonucleotide-other | Phase 1 |
Recent results and decisions
- Oct 27, 2026met Remibrutinib met its primary endpoint of reducing annualized relapse rate versus teriflunomide in Phase III REMODEL-1 and -2 RMS trials, with favorable safety profile.
Positive results from the Phase III REMODEL-1 and -2 trials showed oral remibrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), significantly reducing annualized relapse rate (ARR) versus teriflunomide.
Filing - Oct 27, 2026missed Del-desiran did not meet its primary endpoint of video hand opening time in Phase III HARBOR study in DM1, though evidence of clinical activity was observed in secondary endpoints.
In the Phase III HARBOR study, del-desiran did not meet its primary endpoint of video hand opening time (vHOT) versus placebo in myotonic dystrophy type 1 (DM1).
Filing - Oct 27, 2026missed Pelacarsen did not meet its primary endpoint of reducing cardiovascular events versus placebo in Phase III HORIZON trial, despite reducing Lp(a) levels.
In the Phase III HORIZON trial, pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events versus placebo in patients with elevated Lp(a) and established cardiovascular disease (CVD).
Filing
24 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.